arrow
T

Tae Min Kim

Seoul National University Hospital
H指数:69
被引数:2.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A plain language summary of the SAVANNAH study: savolitinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification whose cancer had grown or spread on osimertinib

SAVANNAH研究的大众语言摘要:色瑞替尼联合奥希替尼用于EGFR突变型晚期非小细胞肺癌患者,这些患者的肿瘤在奥希替尼治疗后出现MET过表达和/或扩增,且肿瘤已进展或扩散。

2026-07-160
OA
Author Correction: SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

作者勘误:靶向SEZ6的抗体药物偶联物ABBV-706在晚期小细胞肺癌和实体瘤中的研究:一项1期临床试验

2026-06-290
OAAI
SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

靶向SEZ6抗体偶联药物ABBV-706在晚期小细胞肺癌和实体瘤中的I期临床试验

2026-06-010
OAAI
Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignancies

度伐利尤单抗,一种人淋巴细胞活化基因-3单克隆抗体,与西米普利单抗联合:在晚期恶性肿瘤中的肿瘤特异性扩展队列

Cancer
IF5.1
2026-04-240
OAAI
A spatially resolved human glioblastoma atlas reveals distinct cellular and molecular patterns of anatomical niches

空间分辨的人类胶质母细胞瘤图谱揭示了解剖微环境中独特的细胞和分子模式

2026-02-200
OA
Incorporation of 5-methylcytidine alleviates RIG-I–mediated innate immune responses to a self-amplifying RNA vaccine

5-甲基胞嘧啶的加入可缓解RIG-I介导的固有免疫反应,以针对自我扩增RNA疫苗

2025-11-120
PRE
Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer

Sevabertinib治疗晚期HER2-Mutant非小细胞肺癌

2025-10-014
PRE
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC

奥希替尼联合化疗在EGFR突变型晚期非小细胞肺癌中的生存情况

2025-10-015
PRE
PROs versus clinician-reported adverse events in a large clinical trial: findings from the Phase 3 POLARIX study

患者报告结果(PROs)与临床医生报告的不良事件在大型临床试验中的比较:来自III期POLARIX研究的结果

Blood
IF23.1
2025-09-290
OA
Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohort

伦伐替尼联合帕博利珠单抗用于先前接受过治疗的特定实体瘤患者:来自LEAP-005研究复发胶质母细胞瘤队列的2期研究结果

Cancer
IF5.1
2025-08-130
OAAI